A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).
J Exp Clin Cancer Res
; 43(1): 100, 2024 Apr 02.
Article
in En
| MEDLINE
| ID: mdl-38566164
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Floxuridine
/
Neoplasms
Limits:
Humans
Language:
En
Journal:
J Exp Clin Cancer Res
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: